Healthcare · Stock picks newsletter
Double Blind Bets: review of price, cadence & strategy
Early-stage biotech explained for investors, beyond management pitches.
Double Blind Bets covers early-stage biotech for investors. The writer says they look beyond management pitches and work through case reports, failed trials, lab work and other companies' data to judge whether a drug is well supported. Prices are the publication's web subscription prices on Substack.
Want to see what you get before paying? Read recent issues in the official archive.
Facts checked on 2026-10-22 at the official page. Prices can change; confirm before you subscribe. We do not publish ratings or performance claims.
Similar newsletters
Motley Fool Epic
The Motley Fool's flagship bundle of monthly stock picks and portfolio guidance.
Motley Fool Stock Advisor
Two stock recommendations a month, plus Top 10 rankings, for long-term investors.
Kiplinger Investing Weekly
A free twice-a-week roundup of stocks, funds and industries to consider or avoid.